More capacities


Abbott Laboratories is to spend a85m and expand its pharmaceutical manu­facturing facility in Sligo (Ireland), saying that would help the company to ensure its supply of compounds in bio­pharmaceutical areas like virology and nephrology. The investment, which will result in the creation of up to 175 jobs, is supported by the country’s investment promotion agency IDA Ireland. The expansion will be completed in 2014, bringing total employment at the site to 300. Azita Saleki-Gerhardt, president of global pharmaceutical operations at Abbott, said the company has had a presence in Ireland for more than 65 years, and that Sligo is an important part of its pharmaceutical manufacturing network. In total, Abbott runs eight manufacturing facilities in Ireland.



Roche has named Thomas Schinecker as the new President of its Branford-based next-generation sequencing center of excellence 454 Life Sciences. The oncologist joined Roche eight years ago and is currently Diagnostics General...



Norwegian cancer therapy developer Clavis Pharma ASA (Oslo) has appointed Nicholas Adams as the firm’s new Chief Business Officer after previous CBO Jan Alfheim took a post as Managing Director at Oslo-based cancer drug delivery...



The European Food Safety Authority (EFSA) has finalised its evaluation of health claims for foods. By the end of the year the European Commission will present a list of permitted claims.Since 2008 the Panel has assessed 2,758...

Politics / Law


Brussels - An accreditation scheme für sustainable biofuels has been presented by the EU. The European Commission accepted seven different models. In order to receive government support or count towards mandatory national...



Brussels - Ipilimumab, an anti-CTLA-4 antibody that was celebrated at this year's ASCO meeting has received approval by the European Commission as a treatment for adult patients with previously-treated advanced melanoma. In...



The shying away from fossil fuels in Europe will generate an increase in lignocellulosic biomass demand of 44% between 2010 and 2020. The increase will be spurred mainly by the energy sector, but will also be used in industrial...

Politics / Law


The European Parliament has backed a report based on proposals from the European Commission (EC), which would allow Member States to ban the cultivation of genetically modified (GM) crops on their territory. Defending its...



Tailored, stratified and more effective – these are a few of the attributesof future drugs. Many of the discussions at the BIO International Conventionthat closed its gates last Thursday hinged around the question how thebiotech...

Politics / Law


The European Commission has relaxed the rules for non-EU approved GMO admixtures in feed imports. It now has decided to accept traces of up to 0.1% GMO in feed materials from third countries provided an EU authorisation for the...

Politics / Law


Ispra – Research on GMOs in Europe is falling sharply, according to the EU’s registry for the deliberate release of GMOs at the Joint Research Centre in Ispra (Italy). In the first six months of this year, releases slid by over...

Displaying results 121 to 130 out of 1983

< Previous 121-130 Next >

© 2007-2015 BIOCOM


LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Product of the week


Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...


All Events



BioVaria 2015

Stock list

All quotes


  • THERAMETRICS0.08 CHF14.29%
  • MEDIGENE10.96 EUR4.88%
  • EVOLVA1.58 CHF3.27%


  • BIOTEST71.00 EUR-3.92%
  • SYNGENTA314.40 CHF-3.65%
  • 4SC5.03 EUR-3.27%


  • 4SC5.03 EUR293.0%
  • WILEX4.33 EUR51.4%
  • SARTORIUS151.00 EUR21.2%


  • CYTOS1.01 CHF-29.4%
  • BIOTEST71.00 EUR-26.9%
  • BIOFRONTERA2.30 EUR-11.2%


  • SANTHERA96.45 CHF2329.5%
  • CYTOS1.01 CHF676.9%
  • WILEX4.33 EUR397.7%


  • MOLOGEN4.94 EUR-55.4%
  • BIOFRONTERA2.30 EUR-29.2%
  • BIOTEST71.00 EUR-20.0%

No liability assumed, Date: 02.05.2015

Current issue

All issues